Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Pancreas Islet Cell Tumor
100%
Neuroendocrine Tumor
60%
Cholangiocarcinoma
56%
Neoplasm
53%
Overall Survival
47%
Recurrent Disease
44%
Pancreas Cancer
42%
Lymph Node
40%
Diseases
38%
Tumor
31%
Recurrence Free Survival
31%
Pancreaticoduodenectomy
26%
Lymph Node Metastasis
24%
Hepatectomy
21%
Chemotherapy
20%
Pancreas Adenocarcinoma
20%
Gastroenteropancreatic Neuroendocrine Tumor
19%
Adjuvant Therapy
17%
Surgeon
16%
Colorectal Liver Metastasis
16%
Long-Term Outcome
15%
Neoadjuvant Therapy
15%
Distal Pancreatectomy
14%
Biological Marker
13%
Metastatic Carcinoma
12%
Quadrantectomy
12%
Neoadjuvant Chemotherapy
12%
Cancer
12%
Chemoradiotherapy
12%
Malignant Neoplasm
12%
Hazard Ratio
11%
Hepatic Portal Vein
11%
Retroperitoneal Lymph Node Dissection
11%
Gemcitabine
11%
Colorectal Carcinoma
9%
Fistula
9%
Liver Metastasis
9%
Bile Duct
9%
Morbidity
9%
Pancreatectomy
9%
Long Term Survival
9%
Arm
9%
Pancreas Fistula
9%
Clinical Trial
8%
Surgery
8%
Computer Assisted Tomography
8%
Systematic Review
8%
Meta-Analysis
8%
Paclitaxel
8%
Surgical Oncology
7%
Keyphrases
Pancreatic Neuroendocrine Tumors (pNETs)
70%
Resection
48%
Curative Resection
37%
Neuroendocrine Tumor
35%
Overall Survival
34%
Recurrence-free Survival
27%
Tumor Studies
24%
Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
24%
Tumor
23%
Surgical Resection
22%
Lymph Node Metastasis
20%
Cholangiocarcinoma
19%
Pancreaticoduodenectomy
19%
Adjuvant Therapy
17%
95% Confidence Interval
16%
Intrahepatic Cholangiocarcinoma (iCCA)
16%
Pancreatic Cancer
14%
Tumor Size
14%
Multi-institutional Study
13%
Hepatectomy
13%
Nonfunctional Pancreatic Neuroendocrine Tumor
12%
Pancreatic Ductal Adenocarcinoma
12%
Patient Outcomes
12%
Colorectal Cancer Liver Metastasis (CRCLM)
12%
Liver
12%
Neoadjuvant Therapy
11%
Borderline Resectable Pancreatic Cancer
11%
Gastrointestinal Tract
10%
Hazard Ratio
10%
Breast Reconstruction
10%
Lymph Node Positive
9%
Neoadjuvant Chemotherapy
9%
R0 Resection
9%
Improved Outcomes
9%
Phase II Trial
8%
Long-term Survival
8%
Perihilar Cholangiocarcinoma
8%
Meta-analysis
8%
Surgical Stress
8%
Nodal Status
8%
Neoadjuvant
7%
United States
7%
Pancreas
7%
Tumor Grade
7%
Oncoplastic Breast Surgery
7%
Distal Pancreatectomy
7%
Hilar Cholangiocarcinoma
6%
Lymphadenectomy
6%
Median Overall Survival
6%
Recurrence Pattern
6%